Redmile Biopharma Investments III

About Redmile Biopharma Investments III

REDMILE BIOPHARMA INVESTMENTS III is associated with Sensorion as an investor and governance vehicle represented on the board by Natalie Berner. Its most notable role in Sensorion’s corporate governance is therefore that of a director representing Redmile Group, making it an important link between the company and one of its key shareholders. In a listed biotech environment, this role carries strategic significance: Sensorion is a clinical-stage company focused on innovative therapies for hearing loss, where long-term R&D execution, regulatory progress, and financing discipline are central to value creation. In Sensorion’s corporate documents, Redmile Bipharma Investments III LP is explicitly listed among the company’s directors, represented by Natalie Berner. The Redmile franchise is therefore closely connected to the company’s financial oversight and strategic direction, particularly in a context where Sensorion has been advancing gene-therapy programs, preparing and progressing clinical trials, and strengthening its development and manufacturing capabilities. Sensorion’s 2023 annual report and 2024 annual report describe continued progress on SENS-501 (OTOF-GT), regulatory approvals enabling the Audiogene Phase 1/2 clinical trial, and ongoing expansion of technical development and pilot-scale manufacturing capacity. The expertise associated with Redmile in the Sensorion ecosystem is that of a life-sciences investor with experience in therapeutic products and biotechnology governance. For a company like Sensorion, such a shareholder representative can play a meaningful role in board-level discussions around capital allocation, financing strategy, clinical execution, and the sequencing of development milestones. This is particularly relevant for a biotech platform operating in a highly specialized field, where scientific ambition must be matched by operational rigor and access to funding over multiple years. More broadly, REDMILE BIOPHARMA INVESTMENTS III’s presence in Sensorion’s governance reflects a commitment to supporting innovation-led healthcare companies with high R&D intensity. Its role is non-executive but strategically important, helping ensure alignment between management, the board, and the investment base as Sensorion advances its clinical and regulatory roadmap.